BSE · 519242
FRESITA PROTEINS LIMITED
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹17 Cr with net profit ₹0 Cr — a 2.75% net margin, versus 0.02% the period before.
Shareholding
As of 2026-09-30
- Promoter80.47%
- Public19.53%
3,352 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.06× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Trading · ranked #153 of 693 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,63,802 Cr | 101.43 | 3.71 | 3.66% | 4.59% |
| Avenue Supermarts Limited | ₹2,24,349 Cr | 71.98 | 8.6 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,68,779 Cr | 88.12 | 21.69 | 24.4% | 8.62% |
| FSN E-Commerce Ventures Ltd. | ₹1,04,618 Cr | 314.83 | 63.16 | 19.49% | 2.85% |
| Aditya Infotech Limited | ₹50,886 Cr | 82.37 | 13.87 | 16.16% | 10.38% |
| Vishal Mega Mart Limited | ₹45,148 Cr | 50.19 | 5.7 | 11.37% | 6.45% |
| Aegis Logistics Limited | ₹42,976 Cr | 32.26 | 6.45 | 20.01% | 14.99% |
| Premier Energies Limited | ₹40,670 Cr | 22.98 | 7.88 | 34.23% | 19.11% |
| Redington Limited | ₹27,339 Cr | 13.62 | 2.54 | 18.62% | 1.31% |
| Honasa Consumer Limited | ₹16,378 Cr | 57.17 | 11.02 | 19.03% | 10.3% |
| FRESITA PROTEINS LIMITED(this company) | ₹198 Cr | 78.08 | 1.12 | 2.87% | 17.14% |
AI analysis
AI-generated · google/gemini-2.5-flashSarda Proteins Ltd. has no specified business activities. The company reported a market capitalisation of Rs 88 Cr. Its PE ratio stands at 137.72, with an EPS of 3.11. The book value per share is Rs 10.57. Sarda Proteins Ltd. has a Return on Equity (ROE) of 21.15% and a Return on Capital Employed (ROCE) of 20.12%. The company's revenue was Rs 24.19 Cr, and it achieved a profit margin of 15.28%.
Positives
- +The company has a negligible debt-to-equity ratio of 0, indicating strong financial leverage management.
- +Promoter shareholding is substantial at 80.66% as of June 30, 2026.
- +There are no reported promoter share pledges, indicating a lack of encumbrance on promoter holdings.
- +The Return on Equity (ROE) is 21.15%, which suggests efficient use of shareholder funds.
- +The Return on Capital Employed (ROCE) is 20.12%, indicating good operational efficiency.
Negatives
- −The company's P/E ratio is high at 137.72.
- −Revenue has seen significant fluctuations, dropping from Rs 10.85 Cr in Mar 2022 to Rs 1.46 Cr in Mar 2024.
- −Net profit has shown inconsistency, including periods of losses such as -Rs 0.03 Cr in Mar 2023.
- −The company is under GSM Stage 4 surveillance, which indicates regulatory concerns.
- −No quarterly results for annual periods other than Mar 2025 and Jun 2026 are provided in the data.
Financial Performance
Sarda Proteins Ltd. reported a revenue of Rs 24.19 Cr. Over the past few years, annual revenue has fluctuated significantly, decreasing from Rs 11.44 Cr in Mar 2021 to Rs 1.46 Cr in Mar 2024, before increasing to Rs 24.19 Cr in Mar 2025. Annual net profit has also shown variability, with losses in Mar 2021 (-Rs 0.02 Cr), Mar 2023 (-Rs 0.03 Cr), and a profit of Rs 0.0051 Cr in Mar 2025.
Profitability & Returns
The company’s profit margin was 15.28%. Sarda Proteins Ltd. delivered a Return on Equity (ROE) of 21.15% and a Return on Capital Employed (ROCE) of 20.12%. The EPS for the latest period was 3.11. Annual EPS performance has varied, moving from -0.12 in Mar 2021 to 11.25 in Mar 2024, and then to 2.96 in Mar 2025.
Balance Sheet
Sarda Proteins Ltd. maintains a debt-free status with a debt-to-equity ratio of 0. The book value per share is Rs 10.57. No dividend yield was reported for the company.
Ownership & Pledges
As of June 30, 2026, the promoters held 80.66% of the shares. Public shareholding stood at 19.34%. There was no reported FII or DII holding. The total number of shareholders was 2897. No promoter share pledging has been reported.
Regulatory & Surveillance
Sarda Proteins Ltd. is currently under GSM (Graded Surveillance Measure) Stage 4 surveillance, indicating potential risks related to price volatility or other market irregularities.
Data as of — price: 2026-11-14 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.